Dezembro 2025 | Hematology, Transfusion and Cell Therapy

CASE REPORT: WIDESPREAD BONE INVOLVEMENT AFTER ALLOGENEIC TRANSPLANTATION IN A PATIENT WITH BIPHENOTYPIC ACUTE LEUKEMIA

Yakup ÜNSAL, Muhammed MURATI, Güler DELİBALTA, Serdar Bedii OMAY

Hematol Transfus Cell Ther. 2025;47 Supl 4:106173

Acesso de texto completo

“Kappa Light-Chain Multiple Myeloma Without Serum M-Spike: A Diagnostic and Therapeutic Challenge in an Elderly Patient”

Birol Güvenç

Hematol Transfus Cell Ther. 2025;47 Supl 4:106174

Acesso de texto completo

Early-Stage Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) in a Young Woman: A Rare Subtype Managed Without Chemotherapy

Birol Güvenç

Hematol Transfus Cell Ther. 2025;47 Supl 4:106175

Acesso de texto completo

GLYCEMIC CONTROL, RENAL FUNCTION, AND HEMATOLOGICAL PARAMETERS: A RETROSPECTIVE REAL-WORLD ANALYSIS

Melike Saday Bozkurt, Ali Turunç

Hematol Transfus Cell Ther. 2025;47 Supl 4:106176

Acesso de texto completo

POEMS SYNDROME: CLINICAL FEATURES, DIAGNOSIS, AND TREATMENT APPROACHES

Serkan Güven

Hematol Transfus Cell Ther. 2025;47 Supl 4:106178

Acesso de texto completo

UPDATES ON TARGETED THERAPIES IN ACUTE MYELOID LEUKEMIA

Ufuk Demirci

Hematol Transfus Cell Ther. 2025;47 Supl 4:106179

Acesso de texto completo

OLD TRADITIONS IN A NEW VILLAGE*… WHY ARE FACTORS STILL NECESSARY? CONTEMPORARY PARADİGMS İN HEMOPHILIA MANAGEMENT AND THE IRREPLACEABLE ROLE OF FACTOR REPLACEMENT

Bariş Yılmaz

Hematol Transfus Cell Ther. 2025;47 Supl 4:106180

Acesso de texto completo

IRON CHELATİON İN MYELODYSPLASTİC SYNDROMES: WHO AND WHEN?

Hande Oğul Sücüllü

Hematol Transfus Cell Ther. 2025;47 Supl 4:106181

Acesso de texto completo

THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)

Emel İşleyen Kaya

Hematol Transfus Cell Ther. 2025;47 Supl 4:106182

Acesso de texto completo

THE TREATMENT ALGORITHM FOR SICKLE CELL DISEASE

Metin Çil

Hematol Transfus Cell Ther. 2025;47 Supl 4:106183

Acesso de texto completo

WALDENSTRÖM MACROGLOBULINEMIA

Zekeriya Aksöz

Hematol Transfus Cell Ther. 2025;47 Supl 4:106184

Acesso de texto completo

REFRACTORY CHRONIC MYELOID LEUKEMIA: A REVIEW OF CURRENT THERAPEUTIC LANDSCAPE AND EMERGING CHALLENGES

DENİZ ÖZMEN

Hematol Transfus Cell Ther. 2025;47 Supl 4:106185

Acesso de texto completo

HYPERCOAGULABILITY: ETIOLOGY, DIAGNOSIS AND TREATMENT PRINCIPLES

Tanju Atamer

Hematol Transfus Cell Ther. 2025;47 Supl 4:106186

Acesso de texto completo

THE PLACE OF IMMUNOTHERAPY IN ALL

Mehmet Bakırtaş

Hematol Transfus Cell Ther. 2025;47 Supl 4:106187

Acesso de texto completo

DIAGNOSIS AND MANAGEMENT OF EOSINOPHILIA

Esra Cengiz

Hematol Transfus Cell Ther. 2025;47 Supl 4:106188

Acesso de texto completo

TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA: CURRENT EVIDENCE, PREDICTORS, AND FUTURE DIRECTIONS

Yunus Çatma

Hematol Transfus Cell Ther. 2025;47 Supl 4:106189

Acesso de texto completo

THE PAST, PRESENT, AND FUTURE OF TRANSFUSION

Mahmut Bayık

Hematol Transfus Cell Ther. 2025;47 Supl 4:106190

Acesso de texto completo

PLATELET FUNCTION DISORDERS: CONTEMPORARY INSIGHTS AND FUTURE DIRECTIONS

Salih Sertaç Durusoy

Hematol Transfus Cell Ther. 2025;47 Supl 4:106191

Acesso de texto completo

CNS INVOLVEMENT IN PRIMARY AND SECONDARY ALL AND TREATMENT STRATEGIES

Sultan Okur Acar

Hematol Transfus Cell Ther. 2025;47 Supl 4:106192

Acesso de texto completo

YEŞİM OYMAK

Hematol Transfus Cell Ther. 2025;47 Supl 4:106193

Acesso de texto completo

OPTIMIZATION OF TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA

Nanişe Gizem Fener

Hematol Transfus Cell Ther. 2025;47 Supl 4:106194

Acesso de texto completo

Filiz Yavaşoğlu

Hematol Transfus Cell Ther. 2025;47 Supl 4:106195

Acesso de texto completo

INNOVATIVE TREATMENTS FOR MYELOFIBROSIS

Aysu Timuroğlu

Hematol Transfus Cell Ther. 2025;47 Supl 4:106196

Acesso de texto completo

CURRENT TREATMENT APPROACHES IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA

Fatma Arikan

Hematol Transfus Cell Ther. 2025;47 Supl 4:106197

Acesso de texto completo

HEPATIC VENO-OCCLUSIVE DISEASE

Barbaros Şahin Karagün

Hematol Transfus Cell Ther. 2025;47 Supl 4:106198

Acesso de texto completo

TREATMENT OF RELAPSED/REFRACTORY DLBCL

Hakan Kalyon

Hematol Transfus Cell Ther. 2025;47 Supl 4:106199

Acesso de texto completo

MODULATION OF INEFFECTIVE ERYTHROPOIESIS IN THALASSEMIA

Şifa Şahin

Hematol Transfus Cell Ther. 2025;47 Supl 4:106200

Acesso de texto completo

STEM CELL MOBILIZATION: AUTOLOGOUS AND ALLOGENEIC

Gülsüm Akgün Çağlıyan

Hematol Transfus Cell Ther. 2025;47 Supl 4:106201

Acesso de texto completo

LABORATORY EVALUATION IN MYELOMA: WHICH TESTS SHOULD BE PREFERRED DURING DIAGNOSIS AND FOLLOW-UP?

Burcu Altındağ Avcı

Hematol Transfus Cell Ther. 2025;47 Supl 4:106202

Acesso de texto completo

ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE: INSIGHTS INTO ETIOPATHOGENESIS

Mahmut Bakır Koyuncu

Hematol Transfus Cell Ther. 2025;47 Supl 4:106203

Acesso de texto completo

CHELATION THERAPY IN THALASSEMIA

Utku Aygüneş

Hematol Transfus Cell Ther. 2025;47 Supl 4:106204

Acesso de texto completo

RELAPS/REFRACTORY MANTLE CELL LYMPHOMA TREATMENT

Damla Ortaboz

Hematol Transfus Cell Ther. 2025;47 Supl 4:106205

Acesso de texto completo

SUMMARY: OPTIMIZATION OF TREATMENT IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL)

Demet Çekdemir

Hematol Transfus Cell Ther. 2025;47 Supl 4:106206

Acesso de texto completo

CRS AND ICANS MANAGEMENT

Mehmet Gündüz

Hematol Transfus Cell Ther. 2025;47 Supl 4:106207

Acesso de texto completo

GRAFT VERSUS HOST DISEASE PROPHYLAXIS

Şebnem İzmir Güner

Hematol Transfus Cell Ther. 2025;47 Supl 4:106208

Acesso de texto completo

CHRONİC LYMPHOCYTIC LEUKEMIA (CLL): IMMUNOGENETICS AND DIAGNOSIS

Meryem Şener

Hematol Transfus Cell Ther. 2025;47 Supl 4:106209

Acesso de texto completo

INTERPRETATION OF GENETIC TESTING IN CHRONIC MYELOPROLIFERATIVE NEOPLASMS

Selver Kurt

Hematol Transfus Cell Ther. 2025;47 Supl 4:106210

Acesso de texto completo

ATYPICAL HEMOLYTIC UREMIC SYNDROME: FROM PATHOPHYSIOLOGY TO THERAPEUTIC ADVANCES

Mustafa Duran

Hematol Transfus Cell Ther. 2025;47 Supl 4:106211

Acesso de texto completo

CURATIVE TREATMENT APPROACHES IN THALASSEMIA

Ömer Doğru

Hematol Transfus Cell Ther. 2025;47 Supl 4:106212

Acesso de texto completo

NON-FACTOR APPROACHES AND NEW HORIZONS

Nurgül Yönyül

Hematol Transfus Cell Ther. 2025;47 Supl 4:106213

Acesso de texto completo

IMMUNE THROMBOCYTOPENİA: PATHOPHYSIOLOGY AND MOLECULAR BIOLOGY

Kübra Yel Uygun

Hematol Transfus Cell Ther. 2025;47 Supl 4:106214

Acesso de texto completo

HIGH-RISK MDS TREATMENT AND INNOVATIONS

Mehmet Çelik

Hematol Transfus Cell Ther. 2025;47 Supl 4:106215

Acesso de texto completo

CURATIVE TREATMENT OPTIONS IN SICKLE CELL DISEASE

Merve Yahşi

Hematol Transfus Cell Ther. 2025;47 Supl 4:106216

Acesso de texto completo

DİAGNOSİS AND TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBİNURİA

Tahsin Yüksel

Hematol Transfus Cell Ther. 2025;47 Supl 4:106217

Acesso de texto completo

ALL IN ADOLESCENT AND YOUNG ADULTS

Mesut Tahta

Hematol Transfus Cell Ther. 2025;47 Supl 4:106218

Acesso de texto completo

WHY I CHOSE HEMATOLOGY ?

Emin Kansu

Hematol Transfus Cell Ther. 2025;47 Supl 4:106219

Acesso de texto completo

DONOR SELECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

İbrahim Eker

Hematol Transfus Cell Ther. 2025;47 Supl 4:106220

Acesso de texto completo

GENE THERAPY IN HEMOPHILIA

Assoc. Prof. Dr. Nihal Karadaş

Hematol Transfus Cell Ther. 2025;47 Supl 4:106221

Acesso de texto completo